Previous 10 | Next 10 |
home / stock / agnpf / agnpf news
VANCOUVER, British Columbia, April 26, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that its lead c...
A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related costs in the US ar...
Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19 Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them ef...
Canada’s Algernon Pharmaceuticals (OTCQB:AGNPF) has filed to uplist its shares to Nasdaq and hold an initial public offering. In a filing, Algernon said it completed a 100-for-1 reverse stock split in November. The size and pricing of the US listing have yet to be determined. Algernon ...
VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has awar...
Algernon Pharmaceuticals (OTCQB:AGNPF) completed enrollment in its phase 2 NP-120 (Ifenprodil) idiopathic pulmonary fibrosis (IPF) and chronic cough study. IPF is a condition in which the lungs become scarred which causes difficulty in breathing. The company expects to report data in calendar...
VANCOUVER, British Columbia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has com...
VANCOUVER, British Columbia, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has recei...
VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of ...
VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has file...
News, Short Squeeze, Breakout and More Instantly...
Algernon Pharmaceuticals Inc - Class A Company Name:
AGNPF Stock Symbol:
OTCMKTS Market:
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report that ifenprodil achieved...
VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it ha...
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its...